Stan Gill

Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study

Alexander E. Perl, Jessica K. Altman, Jörge E. Cortes et al. · The Lancet Oncology · 2017 · 488 citations · Full text

Medicine, Oncology, Pharmacology +10

A randomized, double-blind, placebo (P) controlled, multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab (B) to erlotinib (E) and gemcitabine (G) in patients (pts) with metastatic pancreatic cancer

Walter L. Vervenne, Jaafar Bennouna, Yves Humblet et al. · Journal of Clinical Oncology · 2008 · 50 citations

Medicine, Oncology, Pharmacotherapy +13

Results of a first-in-human, phase I/II trial of ASP2215, a selective, potent inhibitor of FLT3/Axl in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML).

Mark J. Levis, Alexander E. Perl, Jessica K. Altman et al. · Journal of Clinical Oncology · 2015 · 39 citations

Medicine, Oncology, Pharmacology +16

Single-agent erlotinib versus oral etoposide in patients with recurrent or refractory pediatric ependymoma: a randomized open-label study

Regina I. Jakacki, Margaret A. Foley, Julie D. Horan et al. · Journal of Neuro-Oncology · 2016 · 30 citations

Medicine, Oncology, Pediatrics +8

Phase I Study of OSI-7904L, a Novel Liposomal Thymidylate Synthase Inhibitor in Patients with Refractory Solid Tumors

Gernot Beutel, Hilary Glen, Patrick Schöffski et al. · Clinical Cancer Research · 2005 · 29 citations · Full text

Pharmacy, Oncology, Pharmacology +12